removed from the system after the second round. CVI >¼ 0.75 was achieved in 8 (11%) statements in the first round, 44 (61%) statements in the second, 17 (24%) statements in the third and 3 (4%) statements in the 4th round. The final 8 domains included: Pelvic Lymph Node Dissection, Development of the Peri-ureteral Space, Lateral Pelvic Space, Anterior Rectal Space, Control of the Vascular Pedicle, Anterior Vesical Space, Control of the Dorsal Venous Complex, and Apical Dissection (Fig 1) .
INTRODUCTION AND OBJECTIVES: Neoadjuvant chemotherapy in pure urothelial bladder cancer provides a significant survival benefit. However, it is unknown if this benefit persists in histological variants of bladder cancer. We aimed to assess the effect of neoadjuvant chemotherapy on overall survival (OS) and upstaging at radical cystectomy in the five most common histological variants.
METHODS: Querying the National Cancer Data Base, we identified 1,555 patients with histological variants undergoing radical cystectomy for muscle-invasive bladder cancer between 2003-2011. Neoadjuvant chemotherapy was defined as multiagent systemic therapy administered within 180 days prior to surgery. Histological variants were categorized as pure neuroendocrine tumors, squamous cell carcinoma, and adenocarcinoma, or micropapillary and sarcomatoid differentiation. Cox regression models were used to examine the effect of neoadjuvant chemotherapy on overall mortality in each variant subgroup. Logistic regression models estimated the odds of pathological upstaging at radical cystectomy for each histological variant, stratified by the receipt of neoadjuvant chemotherapy.
RESULTS: In multivariate analyses, an OS benefit for neoadjuvant chemotherapy was only found in neuroendocrine tumors (hazard ratio [HR]¼0.64; 95% confidence interval [CI]¼0.45-0.90; P¼0.012). Neuroendocrine tumors (odds ratio [OR]¼0.38; 95% CI¼0.22-0.67; P¼0.001), along with micropapillary (OR¼0.16; 95% CI¼0.05-0.47; P¼0.001) and sarcomatoid differentiated tumors (OR¼0.34; 95% CI¼0.14-0.87; P¼0.025), were less likely to be upstaged at radical cystectomy when treated with neoadjuvant chemotherapy. In squamous cell and adenocarcinoma, no favorable pathological outcomes were seen in patients receiving neoadjuvant chemotherapy vs. radical cystectomy alone (all P>0.08). Specifically, patients with squamous cell carcinoma even trended towards worse pathology (i.e. upstaging) at RC if they received neoadjuvant chemotherapy (OR¼1.81; 95% CI¼[0.93-3.52]; P¼0.081) compared to patients undergoing RC alone.
CONCLUSIONS: Patients with neuroendocrine tumors benefit from neoadjuvant chemotherapy, as evidenced by better OS and lower rates of pathological upstaging at radical cystectomy. In micropapillary and sarcomatoid differentiated tumors, neoadjuvant chemotherapy decreased pathological upstaging at cystectomy. However, this favorable effect did not translate into a statistically significant OS benefit for these patients, potentially due to the aggressive tumor biology.
Source of Funding: None

MP34-12 OVEREXPRESSION OF AUTOPHAGY-RELATED GENE ATG7 PROMOTES BLADDER CANCER INVASION VIA AUTOPHAGIC REMOVAL OF PRE-MRNA PROCESSING PROTEIN AUF1 AND INCREASED STABILITY OF RHOGDI? MRNA IN VITRO AND IN VIVO
Junlan Zhu*, Yang Li, Chuanshu Huang, tuxedo, NY; Xue-Ru Wu, new york, NY INTRODUCTION AND OBJECTIVES: Autophagy is an evolutionarily conserved mechanism that is critical for cellular homeostasis but its involvement in cancer in general has been controversial. Even less is known about the relationship between autophagy and bladder cancer development and progression. Here we explore the role of ATG7, a key autophagy-related regulator, in bladder cancer cell invasion.
METHODS: Expression of ATG7 protein in human bladder cancer specimens, cell lines and N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)-induced mouse invasive bladder cancer specimens were assessed using immunohistochemistry and immunoblotting. After ruling out transcriptional regulation, the possibility of microRNA in ATG7 expression was tested by bioinformatics search for putative miRNAs that could target 3'-UTR of ATG7 mRNA, by assessing the expression of candidate miRNAs in bladder cancer tissues and cell lines and by studying the effects of miRNAs on ATG7 expression with stable transfection. The effects of ATG7 expression on invasion was evaluated after shRNA knockdown. The levels of cell invasion effectors (RhoGDIa, RhoGDIb, Rac1, 2, 3, and RhoA) were also determined. The upstream regulators of RhoGDIb were determined using RNA-IP and verified in xenografted tumors.
RESULTS: ATG7 was markedly and reproducibly upregulated in human muscle-invasive bladder cancers, their cell-line derivatives and mouse invasive bladder cancer induced by BBN. Knockdown of ATG7 in human bladder cancer cell lines UMUC3 and T24 dramatically reduced their invasion. Mechanistic analyses showed that ATG7 overexpression was mediated by miR-190, which was also highly upregulated in bladder cancer tissues and cell lines. miR-190 bound to the 3'-UTR of ATG7 mRNA increasing its stability. A separate mechanism was that ATG7-mediated autophagic response could remove AUF1 protein and reduce AUF1 interaction with RhoGDIb mRNA, leading to Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e431
